Barassi Alessandra, Umbrello Michele, Ghilardi Francesca, Damele Clara Anna Linda, Massaccesi Luca, Iapichino Gaetano, Melzi d'Eril Gian Vico
Laboratorio di Analisi, Ospedale San Paolo, Dipartimento di Scienze della Salute, Università degli Studi di Milano, Milano, Italy.
UO Anestesia e Rianimazione, Polo Universitario San Paolo, Milano, Italy.
Clin Chim Acta. 2015 Jan 1;438:252-4. doi: 10.1016/j.cca.2014.09.008. Epub 2014 Sep 11.
Mid-infrared spectral technology has shown a high degree of promise in detecting glucose in plasma. OptiScan Biomedical has developed a glucose monitor based on mid-infrared spectroscopy that withdraws blood samples and measures plasma glucose. The objective of this study was to evaluate the accuracy and performance of the OptiScanner™ 5000 system on different pools of blood.
This study was performed to validate the blood glucose measurements obtained with the OptiScanner™ 5000 by comparing them to Central Laboratory glucose measurements (VITROS® 5600 Integrated System) as a comparative method across a broad range of glucose values over a three day period to obtain 80-90 paired measurements.
A total of 81 paired measurements, distributed between 33 and 320mg/100mL of glucose, were performed. The aggregate data points were within International Organization for Standardization standards, with 100% of the glucose values within ±15%.
The current study suggests that a mid-IR fixed-wavelength system (OptiScanner) can measure glucose accurately across a wide range of glucose values in plasma of ICU patients.
